AXS-05 Reaches FDA Decision Deadline With April 30 PDUFA Date, Poised to Become Second-Ever Approved Drug for Alzheimer's Agitation
Axsome Therapeutics' AXS-05 faces its FDA verdict on April 30 for Alzheimer's disease agitation, backed by four Phase 3 trials but complicated by one failed study.
Overview
The U.S. Food and Drug Administration has until April 30, 2026, to issue a verdict on AXS-05, an oral combination drug developed by Axsome Therapeutics for the treatment of agitation associated with Alzheimer’s disease. If approved, it would become only the second pharmacological agent in history to carry an FDA label for this indication — a condition that affects the majority of Alzheimer’s patients and for which clinicians have long had few targeted options.
The decision arrives against a backdrop of substantial clinical evidence and one notable setback: three of the four Phase 3 trials supporting the application met their primary endpoints, while the fourth did not.
What We Know
AXS-05 combines two established compounds — dextromethorphan hydrobromide and bupropion hydrochloride — through Axsome’s proprietary metabolic inhibition technology. Dextromethorphan acts as an NMDA receptor antagonist and sigma-1 receptor agonist; bupropion simultaneously inhibits the CYP2D6 enzyme to boost dextromethorphan’s bioavailability and adds norepinephrine and dopamine reuptake inhibition. According to Axsome’s press release on GlobeNewswire, the FDA accepted the supplemental NDA and granted Priority Review — shortening the review window to approximately six months rather than the standard ten — and had previously awarded the drug Breakthrough Therapy designation in June 2020.
The drug is already on the U.S. market under the brand name Auvelity for major depressive disorder, giving the FDA an existing safety record to draw on.
Clinical Trial Results
The ADVANCE-1 Phase 2/3 study, which enrolled 366 participants, demonstrated a statistically significant reduction in agitation scores. As reported by BioPharma Dive, AXS-05 produced a 15.4-point reduction on the Cohen-Mansfield Agitation Inventory (CMAI) at five weeks, compared to 11.5 points for placebo, and also outperformed bupropion alone — establishing the dextromethorphan component as the active driver of benefit. Clinical response rates reached 73 percent for AXS-05 versus 57 percent for placebo.
The ACCORD-1 and ACCORD-2 relapse-prevention trials offered additional support. In the double-blind phase of ACCORD, BioPharma Dive reported that participants on AXS-05 had a 3.6-fold lower risk of agitation relapse compared to those switched to placebo, with relapse rates of 7.5 percent versus approximately 26 percent. ACCORD-2 replicated this finding, showing a statistically significant delay in time to relapse and a relapse incidence of 8.4 percent versus 28.6 percent over 26 weeks.
The safety profile across the trials was characterized as well-tolerated. Most adverse events were mild to moderate; there was no signal of increased mortality, sedation, or cognitive worsening in the drug arms.
The Complicating Factor
The fourth trial, ADVANCE-2, did not meet its primary endpoint. As STAT News reported, participants on AXS-05 showed a 13.8-point reduction in CMAI scores compared to 12.6 points for placebo — a numerically modest and statistically nonsignificant difference. Axsome nonetheless chose to submit the application, arguing that the totality of its four-trial program — three successes and a long-term safety study — provides a sufficient evidentiary basis.
Whether the FDA will agree is the central question heading into the April 30 deadline. No advisory committee meeting has been publicly announced for this application.
The Treatment Landscape
Agitation in Alzheimer’s disease encompasses a wide range of disruptive behaviors — pacing, shouting, aggression, and emotional lability — and is estimated to affect between 45 and 76 percent of patients over the course of their illness. The symptom is associated with faster cognitive decline, greater caregiver burden, and earlier placement in nursing facilities.
For decades, the standard response was off-label use of antipsychotics, sedatives, and mood stabilizers — medications not designed for the indication and carrying their own risk profiles in elderly patients. That changed in May 2023, when the FDA approved brexpiprazole (Rexulti) as the first pharmacological treatment specifically indicated for Alzheimer’s-related agitation. A review published in PubMed Central describes brexpiprazole’s approval as resting on two 12-week randomized controlled trials, with the drug producing statistically significant improvements on the CMAI scale versus placebo. However, brexpiprazole carries an FDA Boxed Warning regarding elevated mortality risk in elderly dementia patients — a concern that applies broadly to antipsychotics used in this population — and acts through serotonin-dopamine modulation, a different mechanistic pathway from AXS-05.
If AXS-05 is approved, clinicians would have two drugs with distinct mechanisms, potentially enabling treatment decisions based on patient history, comorbidities, or prior response.
What We Don’t Know
The FDA has not announced whether it will issue a complete response letter or an approval. The agency may also request additional data or impose labeling restrictions that narrow the approved indication. The one failed Phase 3 trial (ADVANCE-2) introduces uncertainty about how the FDA will interpret the overall evidence package.
It is also unclear how payers will approach coverage, or at what price Axsome would launch the drug if approval is granted — both of which will shape how widely the therapy reaches patients.
Finally, researchers and clinicians have noted that clinical trials for Alzheimer’s agitation often struggle with high placebo response rates, which can erode the apparent drug effect and make consistent replication across multiple trials difficult — a challenge that likely explains the ADVANCE-2 outcome.
Analysis
The April 30 deadline represents the culmination of a development program that began years before the first Alzheimer’s agitation drug was approved. Axsome’s decision to proceed with a mixed evidentiary package reflects a calculated bet that the FDA will weigh three positive Phase 3 studies — including two robust relapse-prevention trials — against a single failed symptomatic study.
For patients and caregivers managing one of dementia’s most distressing symptoms, the significance of the decision extends well beyond market share. Brexpiprazole’s antipsychotic class designation carries mortality warnings that make some clinicians hesitant to prescribe it. AXS-05, which operates through glutamate and dopamine pathways rather than antipsychotic mechanisms, could offer a mechanistically distinct option for patients for whom brexpiprazole is considered unsuitable.
The FDA’s ruling, expected by end of April 2026, will set a precedent for how regulators weigh complex multi-trial packages in a disease area where both therapeutic need and methodological challenges remain acute.